Recently developed monoclonal antibodies, also referred to as “biologics,” target different levels of the eosinophilic/Th2 asthmatic response. Omalizumab blocks the interaction of IgE with its receptor and is approved by the US Food and Drug Administration (FDA) for the treatment of asthma. Mepolizumab and reslizumab are IL-5 antagonists and benralizumab is an IL-5 receptor antagonist—all are also FDA-approved for the treatment of asthma. Dupilumab acts on the IL-4 receptor and affects IL-4 and IL-13; recent studies[6,7,8] show benefit, and it is now approved by the FDA. As a group, this medication class has revolutionized asthma care and improved treatment options for patients with moderate to severe asthma.